Skip to main
LMAT

LeMaitre Vascular (LMAT) Stock Forecast & Price Target

LeMaitre Vascular (LMAT) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 40%
Hold 40%
Sell 0%
Strong Sell 0%

Bulls say

LeMaitre Vascular is poised for continued success with strong growth and cash flow, an expanding product portfolio, and promising international expansion plans. With consistent double-digit growth, improved gross margins, and successful sales, the company has a strong financial position. Additionally, successful regulatory submissions and plans for larger deals indicate potential for further growth and market expansion in the vascular and cardiac surgery fields.

Bears say

LeMaitre Vascular is performing better than expected in terms of sales, with a 12% growth rate and strong adjusted EPS of $0.68. However, the company's profitability may be hindered by higher than expected operating expenses, as well as a significant amount of debt on their balance sheet at $169 million. Additionally, while their sales force has grown, there are still open positions to fill, which could impact their sales in the near future.

LeMaitre Vascular (LMAT) has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 40% recommend Buy, 40% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LeMaitre Vascular and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LeMaitre Vascular (LMAT) Forecast

Analysts have given LeMaitre Vascular (LMAT) a Buy based on their latest research and market trends.

According to 5 analysts, LeMaitre Vascular (LMAT) has a Buy consensus rating as of May 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $112.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $112.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LeMaitre Vascular (LMAT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.